Please use this identifier to cite or link to this item: https://doi.org/10.1002/cam4.177
DC FieldValue
dc.titleEarly detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI
dc.contributor.authorRajendran, R
dc.contributor.authorHuang, W
dc.contributor.authorTang, A.M
dc.contributor.authorLiang, J.M
dc.contributor.authorChoo, S
dc.contributor.authorReese, T
dc.contributor.authorHentze, H
dc.contributor.authorvan Boxtel, S
dc.contributor.authorCliffe, A
dc.contributor.authorRogers, K
dc.contributor.authorHenry, B
dc.contributor.authorChuang, K.H
dc.date.accessioned2020-10-30T01:56:28Z
dc.date.available2020-10-30T01:56:28Z
dc.date.issued2014
dc.identifier.citationRajendran, R, Huang, W, Tang, A.M, Liang, J.M, Choo, S, Reese, T, Hentze, H, van Boxtel, S, Cliffe, A, Rogers, K, Henry, B, Chuang, K.H (2014). Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI. Cancer medicine 3 (1) : 47-60. ScholarBank@NUS Repository. https://doi.org/10.1002/cam4.177
dc.identifier.issn20457634
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/182026
dc.description.abstractAngiogenesis plays a major role in tumor growth and metastasis, with tumor perfusion regarded as a marker for angiogenesis. To evaluate antiangiogenic treatment response in vivo, we investigated arterial spin labeling (ASL) magnetic resonance imaging (MRI) to measure tumor perfusion quantitatively. Chronic and 24-h acute treatment responses to bevacizumab were assessed by ASL and dynamic-contrast-enhanced (DCE) MRI in the A498 xenograft mouse model. After the MRI, tumor vasculature was assessed by CD34 staining. After 39 days of chronic treatment, tumor perfusion decreased to 44.8 ± 16.1 mL/100 g/min (P < 0.05), compared to 92.6 ± 42.9 mL/100 g/min in the control group. In the acute treatment study, tumor perfusion in the treated group decreased from 107.2 ± 32.7 to 73.7 ± 27.8 mL/100 g/min (P < 0.01; two-way analysis of variance), as well as compared with control group post dosing. A significant reduction in vessel density and vessel size was observed after the chronic treatment, while only vessel size was reduced 24 h after acute treatment. The tumor perfusion correlated with vessel size (r = 0.66; P < 0.005) after chronic, but not after acute treatment. The results from DCE-MRI also detected a significant change between treated and control groups in both chronic and acute treatment studies, but not between 0 and 24 h in the acute treatment group. These results indicate that tumor perfusion measured by MRI can detect early vascular responses to antiangiogenic treatment. With its noninvasive and quantitative nature, ASL MRI would be valuable for longitudinal assessment of tumor perfusion and in translation from animal models to human. © 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectangiogenesis inhibitor
dc.subjectbevacizumab
dc.subjectmonoclonal antibody
dc.subjectspin labeling
dc.subjectanimal
dc.subjectblood flow
dc.subjectdrug screening
dc.subjectgenetics
dc.subjecthuman
dc.subjectKidney Neoplasms
dc.subjectmagnetic resonance angiography
dc.subjectmouse
dc.subjectNeovascularization, Pathologic
dc.subjectpathology
dc.subjectspin labeling
dc.subjectAngiogenesis Inhibitors
dc.subjectAnimals
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectMagnetic Resonance Angiography
dc.subjectMice
dc.subjectNeovascularization, Pathologic
dc.subjectRegional Blood Flow
dc.subjectSpin Labels
dc.subjectXenograft Model Antitumor Assays
dc.typeArticle
dc.contributor.departmentDEPT OF PHYSIOLOGY
dc.description.doi10.1002/cam4.177
dc.description.sourcetitleCancer medicine
dc.description.volume3
dc.description.issue1
dc.description.page47-60
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1002_cam4_177.pdf2.99 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

17
checked on Aug 7, 2022

Page view(s)

133
checked on Aug 4, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons